Ogawa Hiroyasu
Department of Molecular Medicine, Osaka University Graduate School of Medicine.
Nihon Rinsho. 2003 Sep;61(9):1549-54.
Bone marrow transplantation(BMT) from genotypically human leukocyte antigen (HLA)-matched siblings improves long-term survival in patients with hematologic malignancies. However, more than 70% of patients who could benefit from allogeneic BMT do not have a matched sibling donor. Furthermore, allogeneic BMT has been limited to young patients because of the increased risk for regimen-related toxicity and graft-versus-host disease(GVHD) that occurs with increasing age. HLA-haploidentical minitransplantation may solve these problems. In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.
来自基因型人类白细胞抗原（HLA）匹配同胞的骨髓移植（BMT）可提高血液系统恶性肿瘤患者的长期生存率。然而，超过70%可从异基因BMT中获益的患者没有匹配的同胞供体。此外，由于与方案相关的毒性以及随着年龄增长而发生的移植物抗宿主病（GVHD）风险增加，异基因BMT一直局限于年轻患者。HLA单倍型相合小型移植可能解决这些问题。在使用由氟达拉滨、白消安和抗T淋巴细胞球蛋白组成的预处理方案以及他克莫司和甲泼尼龙预防GVHD的小型移植中，我们证明了来自HLA单倍型相合相关供体的小型移植是可行的。
